Nephropept NPR-11-2022: Phase II trial registration
PeptidPRO (sponsor listed in registry reproduction) · 2023 · Protocol NPR-11-2022; authorization 340 dated 30 June 2023.
Study findings
The public registry reproduction describes a multicenter double-blind randomized placebo-controlled Phase II protocol. It lists dates of June 2023 to December 2024 and a target of 210 participants. This record contains no numerical efficacy or safety results.
- Population and setting
- Planned registry population: 210 patients with stage 3a–3b CKD and type 2 diabetes
- Evidence type
- Not classified
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Secondary registry reproduction, not the full protocol or a clinical-study report. Dates do not verify completion or actual enrollment.
- Formulation and objective fields differ on strength; dose arms are not inferred. No treatment benefit is asserted.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
ClinLine registry reproduction checked; original regulatory record and results not recovered.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Source type: Trial registration — results not reported
Citation and original source
Original source: PeptidPRO (sponsor listed in registry reproduction). Nephropept NPR-11-2022: Phase II trial registration Protocol NPR-11-2022; authorization 340 dated 30 June 2023. 2023.
Molekul research summary: https://molekul.io/research/nephropept-phase2-registry. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry